XILIO THERAPEUTICS INC (XLO) Stock Analyst Earnings Estimates
NASDAQ:XLO - Nasdaq - US98422T1007 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.344M | 25.381M 300.08% | 25.856M 1.87% | 25.856M | 26.26M 1.56% | 10.1M -61.54% | 121.2M 1,100.00% | |||
| EBITDA YoY % growth | -87.3M -18.71% | -77.233M 11.53% | -58.001M 24.90% | -3.262M 94.38% | -57.57M -1,664.71% | -42.864M 25.54% | -38.168M 10.96% | -14.726M 61.42% | 115.85M 886.71% | |
| EBIT YoY % growth | -89.15M -18.80% | -79.133M 11.24% | -59.645M 24.63% | -55.247M 7.37% | -90.294M -63.44% | -150.894M -67.11% | -211.09M -39.89% | -288.86M -36.84% | -239.37M 17.13% | |
| Operating Margin | N/A | N/A | -940.18% | -217.67% | -349.22% | -583.59% | -803.85% | -2,860.00% | -197.50% | |
| EPS YoY % growth | -3.22 48.63% | -2.78 13.66% | -1.28 53.96% | -0.62 51.87% | -0.81 -31.15% | -1.26 -56.25% | -0.48 61.60% | 0.37 176.04% | 1.10 198.63% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.10 57.92% | -0.16 26.55% | -0.17 14.15% |
| Revenue Q2Q % growth | 7.474M 217.10% | 7.474M 230.27% | 7.474M 333.53% |
| EBITDA Q2Q % growth | -15.726M -14.07% | -17.796M -31.49% | -202K 98.31% |
| EBIT Q2Q % growth | -8.484M 42.18% | -14.746M 0.39% | -17.978M -31.91% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.18 70.97% | 0.10 | -0.28 | -287.60% |
| Q4 2024 Q2Q % growth | -0.20 68.75% | -0.22 | 0.02 | 8.61% |
| Q3 2024 Q2Q % growth | -0.22 63.93% | -0.25 | 0.03 | 11.70% |
| Q2 2024 Q2Q % growth | -0.24 65.71% | -0.23 | -0.01 | -3.31% |
| Q1 2024 Q2Q % growth | -0.62 25.30% | -0.11 | -0.51 | -458.06% |
| Q4 2023 Q2Q % growth | -0.64 21.95% | -0.65 | 0.01 | 0.99% |
| Q3 2023 Q2Q % growth | -0.61 15.28% | -0.82 | 0.21 | 25.21% |
| Q2 2023 Q2Q % growth | -0.70 22.22% | -0.88 | 0.18 | 20.11% |
| Q1 2023 Q2Q % growth | -0.83 -6.41% | -0.89 | 0.06 | 7.22% |
| Q4 2022 Q2Q % growth | -0.82 16.33% | -0.79 | -0.03 | -3.42% |
| Q3 2022 Q2Q % growth | -0.72 96.61% | -0.89 | 0.17 | 18.76% |
| Q2 2022 Q2Q % growth | -0.90 | -0.79 | -0.11 | -14.10% |
| Q1 2022 Q2Q % growth | -0.78 | -0.94 | 0.16 | 16.80% |
| Q4 2021 Q2Q % growth | -0.98 | -1.18 | 0.20 | 16.80% |
| Q3 2021 Q2Q % growth | -21.27 | -1.61 | -19.66 | -1,218.27% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 2.93M | 4.444M | -1.514M | -34.07% |
| Q4 2024 Q2Q % growth | 1.724M | 3.333M | -1.609M | -48.27% |
| Q3 2024 Q2Q % growth | 2.263M | 3.333M | -1.07M | -32.10% |
| Q2 2024 Q2Q % growth | 2.357M | 30.3M | -27.943M | -92.22% |
| Q1 2024 Q2Q % growth | 30.3M | -30.3M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 48.98% | 0% | -64.42% |
| Revenue | 0% | 0% | 0% | -47.15% |